| Village Family Health Care Llc | |
|
1 Brickyard Ln Ste Ee York ME 03909-1681 | |
| (207) 305-0965 | |
| Not Available |
| Full Name | Village Family Health Care Llc |
|---|---|
| Speciality | Family Medicine |
| Location | 1 Brickyard Ln Ste Ee, York, Maine |
| Authorized Official Name and Position | Kerri I Neel (FAMILY NURSE PRACTITIONER) |
| Authorized Official Contact | 2073050965 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Village Family Health Care Llc 1 Brickyard Ln Ste Ee York ME 03909-1681 Ph: (207) 305-0965 | Village Family Health Care Llc 1 Brickyard Ln Ste Ee York ME 03909-1681 Ph: (207) 305-0965 |
| NPI Number | 1790458388 |
|---|---|
| Provider Enumeration Date | 07/29/2021 |
| Last Update Date | 11/04/2021 |
| Medicare PECOS PAC ID | 6406245844 |
|---|---|
| Medicare Enrollment ID | O20211105001125 |
News Archive
The U.S. Food and Drug Administration today approved Nerlynx (neratinib) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer.
MOCON, Inc. announced today that on February 17, 2011, its Board of Directors declared a quarterly cash dividend of ten cents ($0.10) per share, payable on May 20, 2011, to shareholders of record on May 6, 2011. This is a five percent increase over the previous rate of nine and one-half cents per share.
A new study finds that the herb milk thistle may help treat liver inflammation in cancer patients who receive chemotherapy. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that the herb could allow patients to take potent doses of chemotherapy without damaging their liver.
Prostate cancer cells that defy treatment and display heightened tumor-generating capacity can be identified by levels of prostate specific antigen (PSA) expressed in the tumor cells, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports in the May 3 edition of Cell Stem Cell.
› Verified 8 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790458388 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | (* (Not Available)) | Primary |
| Provider Name | Kerri I Neel |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1023074424 PECOS PAC ID: 4880621580 Enrollment ID: I20050725000791 |
News Archive
The U.S. Food and Drug Administration today approved Nerlynx (neratinib) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer.
MOCON, Inc. announced today that on February 17, 2011, its Board of Directors declared a quarterly cash dividend of ten cents ($0.10) per share, payable on May 20, 2011, to shareholders of record on May 6, 2011. This is a five percent increase over the previous rate of nine and one-half cents per share.
A new study finds that the herb milk thistle may help treat liver inflammation in cancer patients who receive chemotherapy. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that the herb could allow patients to take potent doses of chemotherapy without damaging their liver.
Prostate cancer cells that defy treatment and display heightened tumor-generating capacity can be identified by levels of prostate specific antigen (PSA) expressed in the tumor cells, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports in the May 3 edition of Cell Stem Cell.
› Verified 8 days ago
| Provider Name | Holly B James |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1144283482 PECOS PAC ID: 6406861764 Enrollment ID: I20060208000498 |
News Archive
The U.S. Food and Drug Administration today approved Nerlynx (neratinib) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer.
MOCON, Inc. announced today that on February 17, 2011, its Board of Directors declared a quarterly cash dividend of ten cents ($0.10) per share, payable on May 20, 2011, to shareholders of record on May 6, 2011. This is a five percent increase over the previous rate of nine and one-half cents per share.
A new study finds that the herb milk thistle may help treat liver inflammation in cancer patients who receive chemotherapy. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that the herb could allow patients to take potent doses of chemotherapy without damaging their liver.
Prostate cancer cells that defy treatment and display heightened tumor-generating capacity can be identified by levels of prostate specific antigen (PSA) expressed in the tumor cells, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports in the May 3 edition of Cell Stem Cell.
› Verified 8 days ago
| Provider Name | Ashley Mace |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1417444647 PECOS PAC ID: 7719232248 Enrollment ID: I20180625000166 |
News Archive
The U.S. Food and Drug Administration today approved Nerlynx (neratinib) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer.
MOCON, Inc. announced today that on February 17, 2011, its Board of Directors declared a quarterly cash dividend of ten cents ($0.10) per share, payable on May 20, 2011, to shareholders of record on May 6, 2011. This is a five percent increase over the previous rate of nine and one-half cents per share.
A new study finds that the herb milk thistle may help treat liver inflammation in cancer patients who receive chemotherapy. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that the herb could allow patients to take potent doses of chemotherapy without damaging their liver.
Prostate cancer cells that defy treatment and display heightened tumor-generating capacity can be identified by levels of prostate specific antigen (PSA) expressed in the tumor cells, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports in the May 3 edition of Cell Stem Cell.
› Verified 8 days ago
| Provider Name | Teressa P Peck |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1528721883 PECOS PAC ID: 3971997107 Enrollment ID: I20220303001195 |
News Archive
The U.S. Food and Drug Administration today approved Nerlynx (neratinib) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer.
MOCON, Inc. announced today that on February 17, 2011, its Board of Directors declared a quarterly cash dividend of ten cents ($0.10) per share, payable on May 20, 2011, to shareholders of record on May 6, 2011. This is a five percent increase over the previous rate of nine and one-half cents per share.
A new study finds that the herb milk thistle may help treat liver inflammation in cancer patients who receive chemotherapy. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that the herb could allow patients to take potent doses of chemotherapy without damaging their liver.
Prostate cancer cells that defy treatment and display heightened tumor-generating capacity can be identified by levels of prostate specific antigen (PSA) expressed in the tumor cells, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports in the May 3 edition of Cell Stem Cell.
› Verified 8 days ago
News Archive
The U.S. Food and Drug Administration today approved Nerlynx (neratinib) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer.
MOCON, Inc. announced today that on February 17, 2011, its Board of Directors declared a quarterly cash dividend of ten cents ($0.10) per share, payable on May 20, 2011, to shareholders of record on May 6, 2011. This is a five percent increase over the previous rate of nine and one-half cents per share.
A new study finds that the herb milk thistle may help treat liver inflammation in cancer patients who receive chemotherapy. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that the herb could allow patients to take potent doses of chemotherapy without damaging their liver.
Prostate cancer cells that defy treatment and display heightened tumor-generating capacity can be identified by levels of prostate specific antigen (PSA) expressed in the tumor cells, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports in the May 3 edition of Cell Stem Cell.
› Verified 8 days ago
York Primary Care Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1 Brickyard Ln, Suite Cc, York, ME 03909 Phone: 207-361-4902 Fax: 207-363-2502 | |
Strongwater Counseling Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 647 Us Route 1 Unit 14-281, York, ME 03909 Phone: 207-314-1404 | |
York Hospital Physician Practices Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 15 Hospital Dr, York, ME 03909 Phone: 207-363-4321 Fax: 207-351-2153 | |
York Family Practice Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 16 Hospital Drive, York, ME 03909 Phone: 207-363-8430 Fax: 207-351-3006 | |
Hampton Valley Health Center, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 4 Market Place Dr Ste 204, York, ME 03909 Phone: 561-386-5438 Fax: 866-448-6818 | |
York Internal Medicine Pa Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2 Hospital Dr, Suite A, York, ME 03909 Phone: 207-351-3530 Fax: 207-351-3574 |